Loading Events

Assessing Pain & Its Impact In Autosomal Dominant Polycystic Kidney Disease (ADPKD): The ADPKD Pain & Discomfort Scale (ADPKD – PDS)

Thank you for attending, we hope you enjoyed this webinar.

Please tell us what you thought about today’s presentation by taking the survey below:

Assessing Pain & Its Impact In Autosomal Dominant Polycystic Kidney Disease (ADPKD): The ADPKD Pain & Discomfort Scale (ADPKD – PDS)


Autosomal Dominant Polycystic Kidney Disease (ADPKD), an inherited progressive kidney disease, is the fourth leading cause of kidney failure in the US. Approximately 60% of primary complaints for ADPKD patients involved pain.1 Pain can be described as sharp, dull, acute and/or chronic, depending on the source.1 Patients have shared that pain and their large cystic kidneys often limited their daily activities, causing mental and physical fatigue.2 The Autosomal Dominant Polycystic Kidney Disease Pain & Discomfort Scale (ADPKD-PDS) has been developed and validated as a patient-reported outcomes (PRO) tool.2 While pain continues to be a challenging issue for patients with ADPKD and their health care teams, utilizing a validated tool such as the ADPKD-PDS can facilitate patient-health care professionals’ discussions about ADPKD-associated pain and its impact on patients and their families.2
Did you Know?
  • Individuals with ADPKD have identified inadequate pain management and trivialization of their pain by physicians as key concerns, pointing to the need for tools to address ADPKD-related pain.3
  • The ADPKD-PDS tool was developed through a multi-step collaboration involving 26 clinical experts and 298 patient participants (46 patient focus groups across 18 countries).
Why Attend This Webinar?
  • Join us for this webinar to learn more about the impact of pain in patients with ADPKD and how the new ADPKD-PDS tool can enable standardized assessment of the severity and impact of pain/discomfort in clinical trials and practice settings
What You Will Learn
  • Why evaluate pain in ADPKD?
  • Development process of the ADPKD-PDS
  • Types of pain identified and evaluated in this PRO tool
  1. Bajwa ZH et al. Kidney Int. 2004;66:1561-9.
  2. Oberdhan DO et al. Clin J Am Soc Nephrol. 2023;18:213-22.
  3. Cho Y et al. Am J Kidney Dis. 2021;77:255-63.


Pranav Garimella

Pranav Garimella, MBBS, MPH, FASN

Associate Professor of Medicine

University of California San Diego*

Dr Garimella is an Associate Professor of Clinical Medicine and Nephrology at UC San Diego. He is the Director of Acute Dialysis Services at UC San Diego Health and the founding Director of the UCSD PKD Center of Excellence. He received his training in India, Chicago, and completed his fellowship at Tufts University, training in clinical nephrology with a focus on polycystic kidney disease with Dr Ron Perrone. His research endeavors have led to multiple NIH-funded studies and numerous peer-reviewed publications on the topic of kidney diseases. He has an ongoing NIH grant for his research elucidating aspects of kidney disease and has been the recipient of a multitude of teaching and clinical excellence awards. He is also involved in initiatives to develop programs specifically targeted at minority populations in an effort to improve health literacy and potentially clinical outcomes


Josh Gariboldi

Josh Gariboldi, PharmD, BCPS

Nephrology Senior Medical Science Liaison

Otsuka Pharmaceutical Development & Commercialization, Inc.*

Josh Gariboldi, PharmD, BCPS joined Otsuka in January 2021 and is a Medical Science Liaison on our Nephrology East Team, covering the Carolinas and Tennessee. Dr Gariboldi earned his Doctor of Pharmacy degree from the University of Florida in 2012. He has more than eight years of experience as a clinical pharmacist in both the community and hospital settings, most recently at Bon Secours Mercy Health St. Francis Hospital in Greenville, SC. Dr Gariboldi served as a preceptor with Presbyterian College School of Pharmacy, where he instructed students on Advanced Pharmacy Practice rotations. He holds board certifications in both pharmacotherapy and medical affairs.

*Dr Pranav Garimella is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC). Dr Josh Gariboldi is an employee of OPDC.


Related Resources

Join Today for Instant Access to all NephU Offerings.

Membership is free!

Join NephU today at no cost to register for this event and access to other premium content.

  • The NephU Community is collaborating to improve care and the future outcomes for individuals with kidney disease and other related conditions.
  • Quickly learn more about the topics that interest you.
  • Access our library of on-demand kidney health resources
  • Gain key insights from industry experts & though leaders.